The genetic defect associated with decreased response to interferon therapy to Hepatitis C is:
**Core Concept**
Interferon therapy is a treatment for Hepatitis C, which relies on the host's immune system to clear the virus. The effectiveness of interferon therapy can be influenced by genetic factors, particularly those related to the interferon signaling pathway.
**Why the Correct Answer is Right**
The genetic defect associated with decreased response to interferon therapy in Hepatitis C is IL28B (also known as IFNL3). Variants of the IL28B gene, particularly the CC genotype, have been shown to predict a poor response to interferon-based therapy. This is because IL28B encodes a cytokine receptor subunit that plays a crucial role in the interferon signaling pathway, which is essential for the immune response against Hepatitis C virus (HCV). The CC genotype of IL28B leads to reduced expression of the receptor, resulting in impaired interferon signaling and a decreased response to therapy.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to the genetic defect associated with decreased response to interferon therapy in Hepatitis C.
**Option B:** This option is incorrect because it does not specifically relate to the genetic defect associated with interferon therapy in Hepatitis C.
**Option D:** This option is incorrect because it is not a recognized genetic defect associated with decreased response to interferon therapy in Hepatitis C.
**Clinical Pearl / High-Yield Fact**
It is essential to consider the patient's IL28B genotype when deciding on interferon-based therapy for Hepatitis C, as this can significantly impact treatment outcomes. Patients with the CC genotype may require alternative treatment strategies.
**Correct Answer: C. IL28B**